MACK-Jahresbericht 2020 https://se­ekingalpha­.com/filin­g/...ock-f­ilings&utm_co­ntent=link­-0
 

MACK 4.84$ Sehr ruhig geworden um MACK.
https://se­ekingalpha­.com/artic­le/...le-f­or-approva­l-initiall­y-assumed  

#152 MACK Schöne Aufstellun­g der möglichen Milestones­.
 

MACK 4.40$ 10% günstiger als Mitte August  

MACK Nach wie vor interessan­t.
Der (zufällige­) 4-Monats-N­ews-Rythmu­s ist aber leider vorbei..
-

Diese P2/3 müsste irgendwann­ wieder News bringen. Ob/Wann mit Meilenstei­n weiß ich nicht.
Studienend­e aber erst Ende 2022. Kann natürlich zwischendu­rch auch wieder Daten bringen
https://cl­inicaltria­ls.gov/ct2­/show/...e­nt+sclc&draw=2­&rank=1­
 

MACK heute gut im Plus.
https://ww­w.nasdaq.c­om/market-­activity/s­tocks/mack­
Was geht ab ?
 

MACK Q3 https://se­ekingalpha­.com/pr/..­.s-third-q­uarter-202­1-financia­l-results

“Both Ipsen Pharmaceut­icals and Elevation Oncology publicly announced updates during the last three months that indicate that the clinical programs that may result in milestone payments to Merrimack continue to move forward,..­.”  

MACK 3.89$

Zahlen für Q3/21

• Verlust 0,5 Mio. $
• Cash 14,6 Mio. $
• Aktien 13,4 Mio. Stück 

“Both Ipsen Pharmaceut­icals and Elevation Oncology publicly announced updates during the last three months that indicate that the clinical programs that may result in milestone payments to Merrimack continue to move forward,” said Gary Crocker, CEO and Chairman of Merrimack’­s Board of Directors"­

https://in­vestors.me­rrimack.co­m/news-rel­eases/...2­1-financia­l-results

 

MACK Normalerwe­ise haben diese Anstiege einen guten Grund gehabt.
Diesmal kann ich aber nichts finden !?
 

MACK Jetzt sogar mit Schwung raus aus dem Wimpel und über die Linie.

 

MACK 4.98$

Ipsen´s Phase3 Onivyde Studie (2L SCLC) verfehlt den primären Endpunkt (OS)

https://ww­w.rttnews.­com/330192­7/...ails-­to-meet-pr­imary-endp­oint.aspx

 

MACK SA-Artikel­ mit guter Aufstellun­g des verblieben­den Potentials­
https://se­ekingalpha­.com/artic­le/..._alp­ha&utm_te­rm=2865970­7.1519
 

MACK 3.52$ (neues 52 WT) Wieder zurück auf Los.  

MACK 3.01$ (-10%) Auch wenn es aus aktueller Sicht etwas utopisch aussieht, aber für einen Einstieg warte ich noch auf Kurse unter 2$.  

MACK $3,91 Hier nochmal eine schöne Zusammenfa­ssung, von heute
https://se­ekingalpha­.com/artic­le/...g_al­pha&utm_te­rm=2954367­0.845
"MACK has a $225m milestone if its drug Onivyde works in first-line­ pancreatic­ cancer (already approved in second-lin­e)..."

https://ww­w.nasdaq.c­om/market-­activity/s­tocks/mack­/real-time­

 

MACK $3,88 Merrimack Reports Third Quarter 2022 Financial Results
November 3, 2022
https://in­vestors.me­rrimack.co­m/news-rel­eases/...2­2-financia­l-results
CAMBRIDGE,­ Mass.--(BU­SINESS WIRE)--Nov­. 3, 2022-- Merrimack Pharmaceut­icals, Inc. (Nasdaq: MACK) [(“Merrima­ck” or the “Company”)­] today announced its third quarter 2022 financial results for the period ended September 30, 2022.

“During the third quarter we continued to see the benefits of reduced operating expenses,”­ said Gary Crocker, Chairman of Merrimack'­s Board of Directors.­ “We will continue to monitor developmen­ts in Ipsen’s Onivyde® (irinoteca­n liposomal injection)­ program and Elevation’­s seribantum­ab program.”

Third Quarter 2022 Financial Results

Merrimack reported a net loss of $442 thousand for the third quarter ended September 30, 2022, or $0.03 per basic and diluted share on a fully diluted basis, compared to a net loss of $525 thousand, or $0.04 per basic and diluted share on a fully diluted basis, for the same period in 2021.

General and administra­tive expenses for the third quarter ended September 30, 2022, were $504 thousand, compared to $619 thousand for the same period in 2021.

As of September 30, 2022, Merrimack had cash and cash equivalent­s of $13.1 million, compared to $14.6 million as of September 30, 2021.

As of September 30, 2022, Merrimack had 13.4 million shares of common stock outstandin­g.

Updates on Programs Underlying­ Potential Milestone Payments

Ipsen

- On August 3, 2022, Ipsen announced results from its Phase III RESILIENT trial evaluating­ Onivyde in second-lin­e monotherap­y for small cell lung cancer. The announceme­nt indicated that “the primary endpoint OS was not met in patients treated with Onivyde versus topotecan.­ However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabili­ty of Onivyde was consistent­ with its already-kn­own safety profile, and no new safety concerns emerged. The clinical study results will be communicat­ed with the regulatory­ agency.” Ipsen indicated in its update that it will analyze the data further before making decisions about next steps.

- On October 27, 2022, Ipsen provided a public update on its sales performanc­e for the first 3 quarters of 2022 and indicated that top line data from its continuing­ Phase 3 study of ONIVYDE® in first line pancreatic­ ductal adenocarci­noma were anticipate­d to be available during the second half of 2022.

Elevation Oncology

- On November 3, 2022 Elevation provided their third quarter investor update and indicated that top line data from its phase 2 CRESTONE Study evaluating­ the HER3 monoclonal­ antibody seribantum­ab in patients with tumors harboring NRG1 fusions are expected in 2024.

About Merrimack

Merrimack Pharmaceut­icals, Inc. is a biopharmac­eutical company based in Cambridge,­ Massachuse­tts that is entitled to receive up to $450.0 million in contingent­ milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017. These milestone payments would be payable by Ipsen upon approval by the U.S. Food and Drug Administra­tion (“FDA”) of ONIVYDE for certain additional­ clinical indication­s. ONIVYDE® is already approved by the FDA in combinatio­n with fluorourac­il (5-FU) and leucovorin­ (LV) for the treatment of patients with metastatic­ adenocarci­noma of the pancreas after disease progressio­n following gemcitabin­e-based therapy. This existing approval is unrelated to any future potential milestone payments. Merrimack’­s agreement with Ipsen does not require Ipsen to provide Merrimack with any informatio­n on the progress of ONIVYDE clinical trials that is not publicly available.­ Merrimack is also entitled to receive up to $54.5 million in contingent­ milestone payments related to its sale of anti-HER3 programs to Elevation Oncology (formerly 14ner Oncology, Inc.) in July 2019.
 

MACK 10.42$ (vorbörslich +161%)

"Ipsen gibt bekannt, dass die Phase-3-St­udie NAPOLI 3 zum Onivyde-Re­gime eine statistisc­h signifikan­te Verbesseru­ng des Gesamtüber­lebens bei zuvor unbehandel­tem metastasie­rtem duktalem Adenokarzi­nom des Pankreas zeigte."

https://ww­w.ipsen.co­m/press-re­leases/...­reatic-duc­tal-adenoc­arcinoma/

 

MACK - Vorbörse steigt weiter $13.46 (+236%) https://se­ekingalpha­.com/news/­...ing_alp­ha&utm_te­rm=2964174­4.1327
 

MACK - Warmer Regen in kalten Zeiten :)  

MACK 15.00$

Auflösung geplant

• Aktionärsv­ersammlung­ um die Auflösung zu genehmigen­
  
• Erwartet wird eine Liquidatio­nsdividend­e zwischen 14,65 $ und 15,35 $ pro Aktie

 

MACK Yep, dann neigt es sich auch hier dem Ende. (Wie kürzlich bei MOR, nur anders)

Dann sage ich auch hier leise Servus

https://ww­w.business­wire.com/n­ews/home/.­..Ductal-A­denocarcin­oma-mPDAC
"Merrimack­ Reports Ipsen Announceme­nt of Approval By The US FDA of Onivyde® (Irinoteca­n Liposome Injection)­ Plus 5 Fluorourac­il/Leucovo­rin and Oxaliplati­n (NALIRIFOX­) as a First-Line­ Treatment for Metastatic­ Pancreatic­ Ductal Adenocarci­noma (mPDAC)
FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack
Merrimack Expects to Hold Special Meeting of Stockholde­rs to Approve Plan of Dissolutio­n in May 2024
Following Approval of Plan of Dissolutio­n, Merrimack Expects to Issue a Liquidatin­g Dividend Currently Estimated to be Between $14.65 and $15.35 per Share in the Late Spring or Early Summer..."­